Company: BNBX
Filing Date: 2025-10-23
Form Type: 8-K
Source: 0001104659-25-101630
Chunk: 0

Company: BNB PLUS CORP.
Filing Date: 2025-10-23
Form: 8-K
Item: Item 8.01
Chunk 0
---
Item 8.01. Other Events.

On October 22, 2025, Applied
DNA Sciences, Inc. (the “ Company”) announced the closing of its previously announced private placement offerings in which,
(i) the Company sold to certain accredited investors, at an offering price of $3.32 per share, an aggregate of 4,620,485 shares of common
stock of the Company, par value $0.001 per share (the “ Common Stock”), and/or prefunded warrants in lieu thereof (with such
prefunded warrants having an exercise price of $0.0001 per share), and Series E-1 Warrants to purchase 4,620,485 shares of Common Stock
at a per share exercise price of $3.82 (such offering, the “ Cash Offering”); and (ii) the Company sold to certain accredited
investors, at an offering price of $3.32 per share, 3,444,191 prefunded warrants to purchase shares of Common Stock (with such prefunded
warrants having an exercise price of $0.0001 per share) and 3,444,191 Series E-2 Warrants at a per share exercise of $3.82 (such offering,
the “ Cryptocurrency Offering,” and together with the Cash Offering, the “ Offering”).

Gross proceeds from the Offering
included $15.3 million in cash and stablecoins and units of the OBNB trust valued at $11.71 million (as of October 22, 2025).
The Company received 0.126 units of OBNB trust per prefunded warrant and common warrant for a total of 435,638 trust units representing
underlying ownership of 10,647 BNB tokens.

The Company previously disclosed
the Offering in Current Reports on Form 8-K filed with the Securities and Exchange Commission on September 29, 2025 and on October 1,
2025.

On October 22, 2025, the Company
issued a press release announcing the closing and gross proceeds of the Offering. A copy of the press release is included as Exhibit 99.1
hereto and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.